MIT Technology Review @techreview
Ginkgo Biowork's IPO (via a SPAC) is set to be one of the largest ever for a biotechnology company. But is success telling a story and raising money without introducing significant product worth $15 billion? We asked the question. https://t.co/bPaKPY6DOF — PolitiTweet.org